OptiNose, Inc. (OPTN) Analysts See $-0.75 EPS

July 14, 2018 - By Jeanette Kaplan

Analysts expect OptiNose, Inc. (NASDAQ:OPTN) to report $-0.75 EPS on August, 13.After having $-0.81 EPS previously, OptiNose, Inc.’s analysts see -7.41 % EPS growth. The stock decreased 1.47% or $0.41 during the last trading session, reaching $27.44. About 157,126 shares traded. OptiNose, Inc. (NASDAQ:OPTN) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company has market cap of $1.12 billion. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It currently has negative earnings. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.

More notable recent OptiNose, Inc. (NASDAQ:OPTN) news were published by: Nasdaq.com which released: “Optinose CEO Peter Miller and President and COO Ramy Mahmoud Named EY Life Sciences Entrepreneur Of The …” on June 15, 2018, also Globenewswire.com with their article: “Optinose Announces Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals” published on June 21, 2018, Streetinsider.com published: “OptiNose’s (OPTN) Xhance Xperience Continues to Gain Momentum – BMO” on July 12, 2018. More interesting news about OptiNose, Inc. (NASDAQ:OPTN) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” published on June 29, 2018 as well as Nasdaq.com‘s news article titled: “Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal” with publication date: July 02, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: